DDR1 inhibitors can overcome ECM-mediated drug resistance by disrupting DDR1/PYK2/FAK signaling, remodeling the tumor microenvironment, and enhancing the efficacy of conventional chemotherapeutic agents (76, 77). Here, PTK2B is linked to neoplasm.